Healthcare

OPKO Health combines diagnostics, laboratory services, and biopharma assets in one healthcare platform. Revenue is stabilizing after the post-pandemic reset, and partnerships plus royalties could become meaningful if execution improves, making the company worth a closer look.

Omada Health provides digital programs for diabetes, hypertension, musculoskeletal issues, and related chronic conditions. Rapid revenue growth, improving cash flow, and a broader multi-condition platform make it an increasingly notable name in virtual healthcare.

MannKind develops inhaled therapies and drug-delivery technology, with Afrezza and a growing partner-manufacturing platform driving expansion. Revenue growth has been strong, and the business is becoming more diversified as its dry-powder expertise gains broader commercial use.

MoonLake is developing sonelokimab for inflammatory diseases, with hidradenitis suppurativa at the center of its outlook. The appeal comes from a focused strategy, a large unmet-need market, and room to expand into additional indications if clinical progress continues.

MeiraGTx develops gene therapies for eye, neurological, and salivary gland diseases. Recent revenue acceleration, improving cash burn, and progress in Parkinson’s and ophthalmology programs make it a closely watched emerging name in genetic medicine.

MedinCell develops long-acting injectable medicines that can make treatment simpler and more durable. With UZEDY now commercial and a platform built around partnerships, the company has moved into a more tangible phase where pipeline progress can reshape its revenue base.

Latigo Biotherapeutics is developing non-opioid pain medicines in a large unmet-need market. Its focused pipeline and exposure to a strategically important treatment area make it notable, with future value tied closely to clinical progress and pipeline validation.